Why 'MAGAnomics' Isn't Likely To Work
Sustained 3 percent growth is a target the U.S. is unlikely to hit, and some Trump policies might even make it less possible.
The innovative drug Ocrevus looks as if it could be a game-changer for people with MS. But it's very, very expensive. And as with any new medication, the long-term safety risks are unknown.